Future Medicine Co., Ltd. is a synthetic new drug development company, which engages in the development of specialized drugs with high medical unmet needs based on the FOCUS TM platform based on nucleoside derivatives. Its products include Anti-inflammatory/anti-fibrotic agent (FM101), Targeted anticancer drugs (FM301), Immunotherapy (FM401), Metabolic anticancer agent (FM701), Autoimmune disease/Targeted anticancer drugs (FM501), Antiviral (FM203), and Anti-obesity drug (FM801). The company was founded on June 4, 2015 and is headquartered in Seongnam-si, South Korea.